Epstein Secrets

ng "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successfully • Competitive fees - 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACART CAPITAL LLC EFTA_R1_01138845 EFTA02295571 Return on Investment X

- Perkin Elmer, President of Life Sciences & Technology ■ Dan Junius - lmmunogen, CEO • Al Sommers - JHU, Former Dean, School of Public Health • Chris Jones - J Walter Thompson, former CEO • Bill Halter - Lt. Governor, Arkansas DACART CAPITAL LLC EFTA_R1_01138849 EFTA02295575 DA CART CAPITAL L LC San Francisco, Califo

ng "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successfully • Competitive fees — 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACARI CAPI I AL LL, EFTA00506150 Return on Investment Xenogen Jan-98

- Perkin Elmer, President of Life Sciences & Technology • Dan Junius - Immunogen, CEO • Al Sommers - JHU, Former Dean, School of Public Health • Chris Jones - J Walter Thompson, former CEO 111 • Bill Halter - Lt. Governor, Arkansas DAC .ART C:APITAL EFTA00506154 DACART CAPITAL LLC San Francisco, California: Where Biot

ng "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successfully • Competitive fees — 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACARI CAPI I AL LL, EFTA00506197 Advisory Board Thomas Shenk, • Dr. S

Partner • Kevin Hrusovsky - Caliper Life Sciences, CEO • Dan Junius - lmmunogen, CEO • Al Sommers - JHU, Former Dean, School of Public Health • Chris Jones - J Walter Thompson, former CEO Bi l l • Halter - Li. Governor, Arkansas DAC:ART CAPITAL LL, I I /1 EFTA00506201 DACART CAPITAL LLC A Distinguished Building